The estimated Net Worth of Life Sciences Holdings Ltd ... is at least $7.6 million dollars as of 28 June 2019. Life Ltd owns over 25,000 units of Poseida Therapeutics stock worth over $7,535,607 and over the last 8 years Life sold PSTX stock worth over $67,750.
Sign up
Life Ltd PSTX stock SEC Form 4 insiders trading
Life has made over 2 trades of the Poseida Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently Life sold 25,000 units of PSTX stock worth $67,750 on 28 June 2019.
The largest trade Life's ever made was buying 800,000 units of Poseida Therapeutics stock on 26 September 2016 worth over $8,800,000. On average, Life trades about 275,000 units every 335 days since 2016. As of 28 June 2019 Life still owns at least 2,598,485 units of Poseida Therapeutics stock.
You can see the complete history of Life Ltd stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Poseida Therapeutics
Over the last 4 years, insiders at Poseida Therapeutics have traded over $7,666,974 worth of Poseida Therapeutics stock and bought 3,065,405 units worth $15,916,632 . The most active insiders traders include David Hirsch, Life Sciences Holdings Ltd ... et Eric Ostertag. On average, Poseida Therapeutics executives and independent directors trade stock every 18 days with the average trade being worth of $303,665. The most recent stock trade was executed by Eric Ostertag on 8 August 2022, trading 142,857 units of PSTX stock currently worth $500,000.
What does Poseida Therapeutics do?
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
What does Poseida Therapeutics's logo look like?
Complete history of Life Ltd stock trades at Novan Inc et Poseida Therapeutics
Poseida Therapeutics executives and stock owners
Poseida Therapeutics executives and other stock owners filed with the SEC include:
-
Dr. Eric M. Ostertag,
CEO & Director -
Dr. Eric M. Ostertag M.D., Ph.D.,
Exec. Chairman -
Mark J. Gergen J.D.,
CEO & Director -
Mark J. Gergen,
Pres, Chief Bus. Officer & Director -
Harry J. Leonhardt,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Brent Warner,
Pres of Gene Therapy -
Harry J. Leonhardt Esq., J.D.,
Gen. Counsel, Chief Compliance Officer & Corp. Sec. -
Lisa Portale,
Sr. VP of Regulatory Affairs -
Dr. Matthew A. Spear,
Chief Medical Officer -
Dr. Devon J. Shedlock Ph.D.,
Chief Scientific Officer of Cell Therapies -
Sarah Thailing,
Director of Corp. Communications & IR -
Kristin Martin,
Chief People & Admin. Officer -
Kerry D. Ingalls,
Chief Operating Officer -
Johanna M. Mylet CPA,
Chief Financial Officer -
David Hirsch,
Director -
Catherine J Mackey,
Director -
John P. Schmid,
-
Sean Murphy,
Director -
Kristin Yarema,
President and CEO -
Life Sciences Holdings Ltd ...,
-
Pharma Agnovartis Ag Novartis,
-
Rafael Amado,
-
Matthew A. Spear,
Chief Medical Officer -
Kerry D. Ingalls,
Chief Operating Officer -
Harry J Leonhardt,
GC & Chief Compliance Officer -
Brent Warner,
President, Gene Therapy -
Luke Corning,
-
Johanna Mylet,
Chief Financial Officer -
Eric Ostertag,
Director -
Mark J Gergen,
Executive Chairman -
Life Sciences Holdings Ltd ...,
10% owner -
Charles M Baum,
-
Cynthia Collins,
-
Marcea Bland Lloyd,
-
Syed Ali Aamir Rizvi,
Chief Medical Officer